HomeLWB1 • FRA
add
Mesoblast Ltd
Previous close
€14.10
Day range
€13.50 - €13.50
Year range
€8.10 - €17.00
Market cap
2.09B USD
Avg Volume
13.00
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 25.67M | 1,526.81% |
Operating expense | — | — |
Net income | -20.08M | 16.21% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -11.72M | -23.96% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 129.98M | 241.78% |
Total assets | 782.31M | 19.74% |
Total liabilities | — | — |
Total equity | 574.68M | — |
Shares outstanding | — | — |
Price to book | 31.33 | — |
Return on assets | — | — |
Return on capital | -4.89% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -20.08M | 16.21% |
Cash from operations | -15.17M | -46.91% |
Cash from investing | -303.50K | -196.81% |
Cash from financing | -564.00K | 73.55% |
Net change in cash | — | — |
Free cash flow | -11.48M | -1,034.27% |
About
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004. Wikipedia
Founded
2004
Website
Employees
81
